相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Blockade of CB1 or Activation of CB2 Cannabinoid Receptors Is Differentially Efficacious in the Treatment of the Early Pathological Events in Streptozotocin-Induced Diabetic Rats
Dimitris Spyridakos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
The function of the endocannabinoid system in the pancreatic islet and its implications on metabolic syndrome and diabetes
Edgardo Cortes-Justo et al.
ISLETS (2023)
Molecular and Epigenetic Aspects of Opioid Receptors in Drug Addiction and Pain Management in Sport
Filomena Mazzeo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021
Hongjiang Wu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045
Hong Sun et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2022)
Inflammation in obesity, diabetes, and related disorders
Theresa Rohm et al.
IMMUNITY (2022)
Lipid endocannabinoids in energy metabolism, stress and developmental programming
Mariana Macedo Almeida et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2022)
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty
Alexandru Vasincu et al.
BIOLOGY-BASEL (2022)
Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy
Mona F. El-Azab et al.
WORLD JOURNAL OF DIABETES (2022)
Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors
Noah B. C. Piper et al.
BIOCHEMICAL PHARMACOLOGY (2022)
Yin-Yang control of energy balance by lipids in the hypothalamus: The endocannabinoids vs bile acids case
Thomas H. Lee et al.
BIOCHIMIE (2022)
Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future
Zak M. Whiting et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2022)
Yin and yang of cannabinoid CB1 receptor: CB1 deletion in immune cells causes exacerbation while deletion in non-immune cells attenuates obesity
Kathryn Miranda et al.
ISCIENCE (2022)
Cannabis and cannabinoids as an alternative remedy in metabolic syndrome
Claudia Ali Montoya-Alatriste et al.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2022)
Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189
Sahar S. Alghamdi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Cannabidiol-A phytocannabinoid that widely affects sphingolipid metabolism under conditions of brain insulin resistance
Tomasz Charytoniuk et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes
Lauren Van Hove et al.
MICROVASCULAR RESEARCH (2021)
Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes
Jaejin An et al.
BMJ OPEN DIABETES RESEARCH & CARE (2021)
Maternal obesity reverses the resistance to LPS-induced adverse pregnancy outcome and increases female offspring metabolic alterations in cannabinoid receptor 1 knockout mice
Maria Victoria Bariani et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2021)
Estimating the disease burden of Korean type 2 diabetes mellitus patients considering its complications
Juyoung Kim et al.
PLOS ONE (2021)
Understanding the possible role of endocannabinoid system in obesity
Tapan Behl et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2021)
Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data
Sung-Hee Oh et al.
BMC PUBLIC HEALTH (2021)
Targeting the endocannabinoid system in diabesity: Fact or fiction?
Farah Deeba et al.
DRUG DISCOVERY TODAY (2021)
Peripheral CB1R as a modulator of metabolic inflammation
Ji Hye Han et al.
FASEB JOURNAL (2021)
CB1Rs in VMH neurons regulate glucose homeostasis but not body weight
Carlos M. Castorena et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2021)
A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid
Hebaallah Mamdouh Hashiesh et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
An Autonomous Cannabinoid System in Islets of Langerhans
Kanikkai Raja Aseer et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Role of endocannabinoid CB1 receptors in Streptozotocin-induced uninephrectomised Wistar rats in diabetic nephropathy
Jayarami Reddy Medapati et al.
BENI-SUEF UNIVERSITY JOURNAL OF BASIC AND APPLIED SCIENCES (2021)
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
Arnold C. T. Ng et al.
NATURE REVIEWS CARDIOLOGY (2021)
Cannabinoid-sensitive receptors in cardiac physiology and ischaemia
Sarah-Lena Puhl
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)
Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease
Shiran Udi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling
Inmaculada Ruz-Maldonado et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2020)
Involvement of endocannabinoid system, inflammation and apoptosis in diabetes induced liver injury: Role of 5-HT3 receptor antagonist
Mohammad Amini et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
The therapeutic potential of second and third generation CB1R antagonists
Resat Cinar et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes
Federica Zatterale et al.
FRONTIERS IN PHYSIOLOGY (2020)
Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice
Carmelo Quarta et al.
INTERNATIONAL JOURNAL OF OBESITY (2020)
Inverse Agonism of Cannabinoid Receptor Type 2 Confers Anti-inflammatory and Neuroprotective Effects Following Status Epileptics
Ying Yu et al.
MOLECULAR NEUROBIOLOGY (2020)
Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms
Celia Roger et al.
DIABETES (2020)
Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs
Thomas Murphy et al.
BIOMOLECULES (2020)
Cannabinoids and Cannabinoid Receptors: The Story so Far
Fred Shahbazi et al.
ISCIENCE (2020)
A Systematic Review of the Economic Burden of Type 2 Diabetes in Malaysia
Kurubaran Ganasegeran et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Pathophysiology of Type 2 Diabetes Mellitus
Unai Galicia-Garcia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025
Xiling Lin et al.
SCIENTIFIC REPORTS (2020)
Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome
Basma G. Eid et al.
MEDICINA-LITHUANIA (2020)
Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends
Moien Abdul Basith Khan et al.
JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH (2020)
Role of microRNA in CB1 antagonist-mediated regulation of adipose tissue macrophage polarization and chemotaxis during diet-induced obesity
Pegah Mehrpouya-Bahrami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease
Marco Gentili et al.
PHARMACOLOGICAL RESEARCH (2019)
The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice
Vincenzo Micale et al.
FRONTIERS IN PHARMACOLOGY (2019)
What is driving global obesity trends? Globalization or modernization?
Ashley Fox et al.
GLOBALIZATION AND HEALTH (2019)
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development
Thuy Nguyen et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
In-silico designing and characterization of binding modes of two novel inhibitors for CB1 receptor against obesity by classical 3D-QSAR approach
Naveed Khan et al.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING (2019)
Endocannabinoid and Prostanoid Crosstalk in Pain
Baptiste Buisseret et al.
TRENDS IN MOLECULAR MEDICINE (2019)
Prevalence of Overweight and Obesity among Libyan Men and Women
H. Lemamsha et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Diabetic neuropathy
Eva L. Feldman et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Ewa Galaj et al.
CNS DRUGS (2019)
Emerging class of omega-3 fatty acid endocannabinoids & their derivatives
Josephine E. Watson et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2019)
Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow
Jie Wu
ACTA PHARMACOLOGICA SINICA (2019)
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Kaavya Krishna Kumar et al.
CELL (2019)
A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice
Ji Hye Han et al.
FASEB JOURNAL (2019)
Progress in brain cannabinoid CB2 receptor research: From genes to behavior
Chloe J. Jordan et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2019)
The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives
Sotirios Tsalamandris et al.
EUROPEAN CARDIOLOGY REVIEW (2019)
Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes
Yurii Saroz et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2019)
Modulation of Renal GLUT2 by the Cannabinoid-1 Receptor: Implications for the Treatment of Diabetic Nephropathy
Liad Hinden et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?
Cecilia J. Hillard
NEUROPSYCHOPHARMACOLOGY (2018)
Kinetics of human cannabinoid 1 (CB1) receptor antagonists: Structure-kinetics relationships (SKR) and implications for insurmountable antagonism
Lizi Xia et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Impact of Dietary Fats on Brain Functions
Rosanna Chianese et al.
CURRENT NEUROPHARMACOLOGY (2018)
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity
Ji H. Han et al.
DIABETES OBESITY & METABOLISM (2018)
Obesity and diabetes-Not only a simple link between two epidemics
Agata Chobot et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2018)
Neuroprotective effect of cannabinoid receptor 1 antagonist in the MNU-induced retinal degeneration model
Yuanyuan Chen et al.
EXPERIMENTAL EYE RESEARCH (2018)
Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice
Haiming Ma et al.
FRONTIERS IN PHARMACOLOGY (2018)
LH-21, A Peripheral Cannabinoid Receptor 1 Antagonist, Exerts Favorable Metabolic Modulation Including Antihypertensive Effect in KKAy Mice by Regulating Inflammatory Cytokines and Adipokines on Adipose Tissue
Ziqi Dong et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy
F. Barutta et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Use of healthcare services and expenditure in the US in 2025: The effect of obesity and morbid obesity
Michele Cecchini
PLOS ONE (2018)
Cardiovascular Complications of Marijuana and Related Substances: A Review
Amitoj Singh et al.
CARDIOLOGY AND THERAPY (2018)
Endocannabinoids and related N-acylethanolamines: biological activities and metabolism
Kazuhito Tsuboi et al.
INFLAMMATION AND REGENERATION (2018)
Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity
Lingling Sun et al.
JOURNAL OF NEUROINFLAMMATION (2017)
The CB1 Receptor as the Cornerstone of Exostasis
Pier Vincenzo Piazza et al.
NEURON (2017)
Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11C] RS-016 targeting CB2 in atherosclerosis
Romana Meletta et al.
NUCLEAR MEDICINE AND BIOLOGY (2017)
Cannabinoid Receptors Modulate Neuronal Morphology and AnkyrinG Density at the Axon Initial Segment
Monica Tapia et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2017)
Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review
Marco Koch
FRONTIERS IN NEUROSCIENCE (2017)
Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice
Wei Chen et al.
FRONTIERS IN PHARMACOLOGY (2017)
Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics
Ping Li et al.
FRONTIERS IN PHARMACOLOGY (2017)
Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
Ken Soderstrom et al.
FRONTIERS IN PHARMACOLOGY (2017)
The cannabinoid ligand LH-21 reduces anxiety and improves glucose handling in diet-induced obese pre-diabetic mice
Silvana Y. Romero-Zerbo et al.
SCIENTIFIC REPORTS (2017)
The Role of Brain in Energy Balance
Paulo Matafome et al.
OBESITY AND BRAIN FUNCTION (2017)
Molecular control of regulatory T cell development and function
Yohko Kitagawa et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Rimonabant improves metabolic parameters partially attributed to restoration of high voltage-activated Ca2+ channels in skeletal muscle in HFD-fed mice
B. Chen et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2017)
Role of the endocannabinoid system in diabetes and diabetic complications
G. Gruden et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
The CB2 receptor and its role as a regulator of inflammation
Caroline Turcotte et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Prior Cannabis Use Is Associated with Outcome after Intracerebral Hemorrhage
Mario Di Napoli et al.
CEREBROVASCULAR DISEASES (2016)
Long-term side effects of glucocorticoids
Merih Oray et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update
Paula Morales et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2016)
Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation
F. Rossi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Blockade of cannabinoid 1 receptor improves GLP-1R mediated insulin secretion in mice
Isabel Gonzalez-Mariscal et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Lei Li et al.
ONCOLOGY LETTERS (2016)
Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis
Resat Cinar et al.
JCI INSIGHT (2016)
A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis
W. -C. Hsiao et al.
DIABETES OBESITY & METABOLISM (2015)
Neuroinflammation in Alzheimer's disease
Michael T. Heneka et al.
LANCET NEUROLOGY (2015)
Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture
Katarzyna Malenczyk et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Anti-TNF therapy: past, present and future
Claudia Monaco et al.
INTERNATIONAL IMMUNOLOGY (2015)
Motor, Visual and Emotional Deficits in Mice after Closed-Head Mild Traumatic Brain Injury Are Alleviated by the Novel CB2 Inverse Agonist SMM-189
Anton Reiner et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist
Chaela Presley et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Prospective therapeutic agents for obesity: Molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists
Mayank Kumar Sharma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
New insights on food intake control by olfactory processes: The emerging role of the endocannabinoid system
Edgar Soria-Gomez et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy
Tony Jourdan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Low Brain CB1 Receptor Occupancy by a Second Generation CB1 Receptor Antagonist TM38837 in Comparison With Rimonabant in Nonhuman Primates: A PET Study
Akihiro Takano et al.
SYNAPSE (2014)
Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion
Rentian Feng et al.
BMC PHARMACOLOGY & TOXICOLOGY (2014)
Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2) 27 rats
Chris L. Schaich et al.
PHYSIOLOGICAL REPORTS (2014)
Identification of raloxifene as a novel CB2 inverse agonist
Pritesh Kumar et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects
Linda E. Klumpers et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Modulating the endocannabinoid system in human health and disease successes and failures
Pal Pacher et al.
FEBS JOURNAL (2013)
CB1 blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans
R. Bergholm et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome
Svetlana Slavic et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Cannabinoid Receptor 2: Potential Role in Immunomodulation and Neuroinflammation
Slava Rom et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2013)
Monoacylglycerol Lipase (MAGL) Inhibition Attenuates Acute Lung Injury in Mice
Carolina Costola-de-Souza et al.
PLOS ONE (2013)
Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention
Alok Kumar et al.
BRAIN BEHAVIOR AND IMMUNITY (2012)
Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro
L. S. Whyte et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Hindbrain Neurons as an Essential Hub in the Neuroanatomically Distributed Control of Energy Balance
Harvey J. Grill et al.
CELL METABOLISM (2012)
Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance
Joseph Tam et al.
CELL METABOLISM (2012)
Blockade of Cannabinoid Receptor 1 Improves Insulin Resistance, Lipid Metabolism, and Diabetic Nephropathy in db/db Mice
D. H. Nam et al.
ENDOCRINOLOGY (2012)
Adiponectin: Regulation of its production and its role in human diseases
Adeeb Shehzad et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2012)
Fatty acid flux and oxidation are increased by rimonabant in obese women
Katharine Backhouse et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant
Charlotte Heppenstall et al.
NUTRITION JOURNAL (2012)
The Endocannabinoid System: Role in Energy Regulation
Thomas F. Gamage et al.
PEDIATRIC BLOOD & CANCER (2012)
Cannabinoids Induce Pancreatic β-Cell Death by Directly Inhibiting Insulin Receptor Activation
Wook Kim et al.
SCIENCE SIGNALING (2012)
Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis
Simona Pisanti et al.
BLOOD (2011)
Mechanisms of Osteoclastogenesis Inhibition by a Novel Class of Biphenyl-Type Cannabinoid CB2 Receptor Inverse Agonists
Wolfgang Schuehly et al.
CHEMISTRY & BIOLOGY (2011)
Cannabinoids Inhibit Insulin Receptor Signaling in Pancreatic β-Cells
Wook Kim et al.
DIABETES (2011)
Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line
A. B. El-Remessy et al.
DIABETOLOGIA (2011)
Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity
Alessandra Quercioli et al.
EUROPEAN HEART JOURNAL (2011)
Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease
Sreemanti Basu et al.
IMMUNOLOGIC RESEARCH (2011)
Potential Role of Nuclear Factor kappa B in Diabetic Cardiomyopathy
O. Lorenzo et al.
MEDIATORS OF INFLAMMATION (2011)
Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons
Mayur Patil et al.
NEUROPHARMACOLOGY (2011)
Efficacy and Safety of CP-945,598, a Selective Cannabinoid CB1 Receptor Antagonist, on Weight Loss and Maintenance
Louis J. Aronne et al.
OBESITY (2011)
Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas
Chen Li et al.
PHARMACOLOGY & THERAPEUTICS (2011)
Energy balance regulation by endocannabinoids at central and peripheral levels
Carmelo Quarta et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Changyu Pan et al.
JOURNAL OF OBESITY (2011)
Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract
Carlos Sostres et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2010)
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity
John R. Hadcock et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Functionally selective cannabinoid receptor signalling: Therapeutic implications and opportunities
Barbara Bosier et al.
BIOCHEMICAL PHARMACOLOGY (2010)
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents
N. L. Cluny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Discovery of 1-(2,4-Dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a Potential Peripheral Cannabinoid-1 Receptor Inverse Agonist
Ming-Shiu Hung et al.
CHEMMEDCHEM (2010)
Endocannabinoid Binding to the Cannabinoid Receptors: What Is Known and What Remains Unknown
Patricia H. Reggio
CURRENT MEDICINAL CHEMISTRY (2010)
CB1 Cannabinoid Receptors and their Associated Proteins
Allyn C. Howlett et al.
CURRENT MEDICINAL CHEMISTRY (2010)
A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
M. S. Kipnes et al.
DIABETES OBESITY & METABOLISM (2010)
Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution
M. Frost et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
L. J. Aronne et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
J. Proietto et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Inhibition of titanium particle-induced inflammatory osteolysis through inactivation of cannabinoid receptor 2 by AM630
D. C. Geng et al.
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A (2010)
Signal transduction of the CB1 cannabinoid receptor
Gabor Turu et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2010)
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant
Elena Martin-Garcia et al.
JOURNAL OF NEUROCHEMISTRY (2010)
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
Eric J. Topol et al.
LANCET (2010)
A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low-Calorie Diet
Thomas A. Wadden et al.
OBESITY (2010)
In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB2 receptor inverse agonists
Maria Grazia Cascio et al.
PHARMACOLOGICAL RESEARCH (2010)
Expression and function of cannabinoid receptors in mouse islets
Chen Li et al.
ISLETS (2010)
Effect of Rimonabant on the High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat The ADAGIO-Lipids Trial
Jean-Pierre Despres et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
The role of the pancreatic endocannabinoid system in glucose metabolism
Francisco J. Bermudez-Silva et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity
Javier Palazuelos et al.
BRAIN (2009)
Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis
David R. Janero et al.
EXPERT OPINION ON EMERGING DRUGS (2009)
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation
Guy A. Cabral et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Cannabinoid CB2 Receptor Potentiates Obesity-Associated Inflammation, Insulin Resistance and Hepatic Steatosis
Vanessa Deveaux et al.
PLOS ONE (2009)
The endocannabinoid system: Role in glucose and energy metabolism
Ruben Nogueiras et al.
PHARMACOLOGICAL RESEARCH (2009)
The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation
Vincenzo Di Marzo
PHARMACOLOGICAL RESEARCH (2009)
Identification of intracellular carriers for the endocannabinoid anandamide
Martin Kaczocha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways
Fabrizio Montecucco et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2008)
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain
J. Guindon et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists
C. A. Lunn et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
CB2 receptor-mediated migration of immune cells: it can go either way
A. M. Miller et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake
Carol Addy et al.
CELL METABOLISM (2008)
Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor
Aymen I. Idris et al.
ENDOCRINOLOGY (2008)
Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats
Andreas W. Herling et al.
ENDOCRINOLOGY (2008)
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors:: two year results from the RIO-Europe Study
Luc F. Van Gaal et al.
EUROPEAN HEART JOURNAL (2008)
Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice
Nigel Irwin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: Results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers
Carol Addy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers
Carol Addy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
CB1 receptor blockade and its impact on cardiometabolic risk factors: Overview of the RIO programme with rimonabant
A. J. Scheen
JOURNAL OF NEUROENDOCRINOLOGY (2008)
Cannabinoid receptors: Where they are and what they do
K. Mackie
JOURNAL OF NEUROENDOCRINOLOGY (2008)
Signaling via CNS cannabinoid receptors
Ken Mackie
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
P38 MAP Kinase Signaling Is Required for the Conversion of CD4+CD25-T Cells into iTreg
Samuel Huber et al.
PLOS ONE (2008)
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro
A. Thomas et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms
Claudio Pagano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats
P. Janiak et al.
KIDNEY INTERNATIONAL (2007)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Robin Christensen et al.
LANCET (2007)
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Magali Gary-Bobo et al.
HEPATOLOGY (2007)
Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system
P. V. Piazza et al.
DIABETES & METABOLISM (2007)
Blood-brain barrier delivery
William M. Pardridge
DRUG DISCOVERY TODAY (2007)
The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists
G. T. Whiteside et al.
CURRENT MEDICINAL CHEMISTRY (2007)
Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function
James Ellis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
FRET-based monitoring of conformational change of the β2 adrenergic receptor in living cells
J Nakanishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo
CA Lunn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cannabinoid receptors regulate Ca2+ signals and insulin secretion in pancreatic β-cell
P Juan-Picó et al.
CELL CALCIUM (2006)
The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats
AB Need et al.
PSYCHOPHARMACOLOGY (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification and functional characterization of brainstem cannabinoid CB2 receptors
MD Van Sickle et al.
SCIENCE (2005)
Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice
Y Ueda et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
YL Liu et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study
C Montero et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2005)
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
CR Trillou et al.
INTERNATIONAL JOURNAL OF OBESITY (2004)
SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor:: Biochemical and pharmacological characterization
M Rinaldi-Carmona et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function
K Kristiansen
PHARMACOLOGY & THERAPEUTICS (2004)
Voluntary exercise augments acute effects of CB1-receptor inverse agonist on body weight loss in obese and lean mice
D Zhou et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2004)
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
M Bensaid et al.
MOLECULAR PHARMACOLOGY (2003)
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats
PJ McLaughlin et al.
BEHAVIOURAL PHARMACOLOGY (2003)
Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol
TC Kirkham et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
AC Howlett et al.
PHARMACOLOGICAL REVIEWS (2002)
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor -: Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells
T Sugiura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
